Amneal Pharmaceuticals Inc. [NYSE:AMRX] shares were trading 6.49% to $4.68 on Wednesday. Comparativley, The S&P 500 is trading at 0.55%. For the year, the stock is trading -8.92% and the five-day change stands at 13.14%.
AMRX’s next earning date is 11/04/2020. Currently, the company is booking earnings per share of -1.56 with the price-to-cash-flow at 4.59.
The company is also reporting -1.56 earnings per share.
The Price is right
Holding a Market Cap of $1.30 billion, Amneal Pharmaceuticals Inc. has seen a trading range over the last year of $2.40-$5.79.
For the last five days, AMRX is up from its last closing price. The average shares trading hands each day is 1.11M, with average 10-day volume coming in at 0.77 million.
Using a Force Index Indicator is a good way to look at how strong actual buying and selling pressure is for AMRX. When we apply the Elder Force Index to Amneal Pharmaceuticals Inc., we are seeing an Elder Force Indicator number of 238582.71.
The recent performance of the stock is another area that can tell traders how to proceed. AMRX is presenting an interesting case. This can be seen in the Forward P/E ratio, which currently stands at 6.33. Moreover, the company’s enterprise value has gone from $3.58B to $3.13B quarter-over-quarter. Obviously, the company is heading in the wrong direction, but there are still opportunities for growth in the sector.
In the last quarter, AMRX made a profit of 144.24 million. Amneal Pharmaceuticals Inc. also saw quarter revenue growth year over year of -2.20%. In addition, the company has operating cash flow of $317.29 million.
Looking at popular technical indicators, the company’s 5-day moving average is 4.28 compared to the 50-day moving average of 4.0171. So, we are clearly seeing an upward trajectory here.
The Relative Strength Index or RSI is an indicator ranging between 0 and 100 that traders use to determine if a stock is “overbought” or “oversold.” A strong uptrend tending to reach into the “overbought” status is above 70, while a downward trend will stay around the 30 mark. AMRX currently holds a 9-day RSI of 74.70%, while 100-day RSI stands at 50.56%.
Another indicator we believe is worth keeping tabs on is the Moving Average Convergence Divergence or MACD. Similar to the concept of the Force Index — on the basis of price momentum — the MACD gives traders a tool to measure the turning point of a stock even during rapid fluctuations in price. Buy and sell signals are determined by a stock’s relation to the zero line, so if a stock is above a zero line for many weeks it might be a “buy.” On the other hand, if a stock is below the zero line consistently, it might be one to stay away from. Also, if the MACD line reaches a peak and dips, its momentum may be waning. AMRX’s 9-day MACD is 0.29 and the company’s 100-day MACD stands at -0.03.
Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can maybe gather important information from reading the tea leaves about who is buying and selling.
The major holders for this stock are 10.36% by insiders and 69.44% by institutions. Regarding institutional holdings, Fosun International Ltd owns 14.59%, while the second top holder, Tpg Group Holdings (sbs) Advisors, Inc., currently owns 10.99%.
Over the last six months, insiders have bought 10,000 with the most recent transaction from Kiely John, Director, with a purchase at price 4.40 per share.
Overall, the recommended rating for AMRX is Hold. Currently, the company has 11 analysts watching the stock, and the average quarterly earnings estimate is 0.12. Quarterly revenue estimates are averaging 477.63M with the high estimate reaching 493.8M and the low at 458.69M.
To review, the current 1-year target estimate is sitting at 4.25, while the current price 4.68. Based on this, we expect some pullback on the stock over time given our above analysis.